NEW YORK (GenomeWeb News) — Igenica today said it has completed a Series B financing round, raising $24 million.
The round was led by The Column Group, OrbiMed Advisors, and 5AM Ventures. The funds will be used to expand and accelerate Igenica's drug discovery and development efforts using its proteomics- and antibody-based platforms, Igenica said in a statement.
The proteomics platform, called sTAg, identifies new surface antigens that are amenable to antibody targeting in cancer. The monoclonal antibody platform, called iTAb, is a function-based de novo method for generating and screening antibody drug candidates against tumor antigens.
Based in Burlingame, Calif., Igenica previously had raised about $5 million.